Discovery of Onglyza (Saxagliptin): A long-Acting Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type II Diabetes
See two videos of RBHS strategic plan speaker series presentations made by Drs. David Augeri and Brian Strom regarding drug discovery, approval, and marketing of Saxagliptin (Dr. Augeri) and the post-marketing surveillance of that drug (Dr. Strom).
